graft-versus-host disease - Articles and news items

Xenikos’ T-Guard trial doses final patient with acute graft-versus-host disease

Industry news / 21 September 2016 / Niamh Louise Marriott, Digital Content Producer

T-Guard has been shown to be well tolerated, with a manageable side effect profile and no severe infusion reactions in patients with acute GVHD…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+